Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Yesafili, received marketing authorization approval from the European Commission for the European Union
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Total transaction value of the divestment is Rs. 3,660 million
This product will be manufactured at Lupin’s Pithampur facility in India
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Research released at UN General Assembly week shows tests predicting heart disease and diabetes are among lowest cost solutions for improving Indian health
AHH will make an investment of Rs. 600 crore in the company through a mix of primary and secondary infusion
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
Subscribe To Our Newsletter & Stay Updated
